Opiant Pharmaceuticals, Inc. (Opiant), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced that the last patient has been enrolled in the phase 2 clinical trial of OPNT002, nasal naltrexone, for patients with alcohol use disorder (AUD). The total trial duration per patient is 20 weeks, with the last patient enrolled expected to complete the study in early 2023 and with top line data anticipated to follow mid-year. "We are pleased to have completed patient enrollment ahead of schedule and are looking forward to concluding the treatment phase of this study and releasing top-line data next year,
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!